Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Other Non-Current Assets (2022 - 2025)

Oramed Pharmaceuticals' Other Non-Current Assets history spans 4 years, with the latest figure at $2000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets changed N/A year-over-year to $2000.0; the TTM value through Dec 2025 reached $2000.0, changed N/A, while the annual FY2025 figure was $2000.0, N/A changed from the prior year.
  • Other Non-Current Assets reached $2000.0 in Q4 2025 per ORMP's latest filing, down from $40000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $40000.0 in Q3 2025 to a low of $2000.0 in Q2 2024.
  • Average Other Non-Current Assets over 4 years is $12181.8, with a median of $7000.0 recorded in 2022.
  • Peak YoY movement for Other Non-Current Assets: plummeted 71.43% in 2024, then surged 1900.0% in 2025.
  • A 4-year view of Other Non-Current Assets shows it stood at $7000.0 in 2022, then soared by 285.71% to $27000.0 in 2023, then plummeted by 92.59% to $2000.0 in 2024, then changed by 0.0% to $2000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Other Non-Current Assets are $2000.0 (Q4 2025), $40000.0 (Q3 2025), and $2000.0 (Q2 2025).